FLASCO Board Member Discusses Evolving Treatment Options for Patients With mCRPC
- FLASCO
- September 16, 2016
- News
Richard M. Levine, MD, FLASCO Board Member and Past President, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer (mCRPC). See the video